Clearing worn-out cells, and a GLP-1 tablet
Also this week
Immune cells clear worn-out cells less well as a recycling system fades
Your cells run a sorting service for worn proteins. It picks out single damaged proteins by name, tags them, and feeds them into a compartment that breaks them down. The technical name is chaperone-mediated autophagy. A new paper reports that this system declines with age, and that the decline leaves macrophages less able to clear senescent cells. Macrophages are the immune cells that swallow and digest debris. Senescent cells have stopped dividing but stay alive and keep signalling. Background: senescent cells release inflammatory proteins and enzymes that remodel nearby tissue, which is why they are studied as a source of long-running, low-grade inflammation. In young tissue, most are removed as they appear. This paper points at the removal side. Only the title and central claim were available, so the species, the numbers and the size of the effect are not established here. A declining process alongside a declining function does not prove one caused the other.
Source: Nature Aging Peer-reviewed
A GLP-1 drug built as an ordinary tablet was tested in early type 2 diabetes
A trial tested safiglipron, a drug taken by mouth, against a dummy tablet in people with early type 2 diabetes. Neither the participants nor the researchers knew who got which. Safiglipron acts at the GLP-1 receptor, the docking point used by a gut hormone released when you eat. That hormone tells the pancreas to release insulin when blood sugar is high, slows stomach emptying, and reduces appetite. Background: most GLP-1 medicines are peptides, short protein chains that the gut digests easily, so they are usually injected. Safiglipron is a small molecule, a smaller and sturdier chemical that can survive digestion. That changes cost and practicality rather than biology. The results, the number of participants and the trial length were not available, so nothing here tells you whether it worked or how it was tolerated. Short trials in early disease measure blood markers, not heart or kidney outcomes over years. Outcomes vary between individuals.
Source: Nature Medicine Peer-reviewed
